Hinova Pharmaceuticals' HP515 Featured at the 13th SOMS International Congress on Obesity and Metabolic Syndrome 2025
On November 29, 2025, at the 13th SOMS International Congress on Obesity and Metabolic Syndrome, Dr. Li Xinghai, Chief Scientific Officer (CSO) of Hinova Pharmaceuticals, was invited by the Congress Chair to deliver an important presentation at a special symposium titled "A New Role for THR-β Agonists: Beyond Liver Disease — Protecting Skeletal Muscle Mass." The presentation showcased the company's leading capabilities in innovative drug development for metabolic diseases.
SOMS International Congress on Obesity and Metabolic Syndrome
As a premier academic event in the field of obesity and metabolism in Asia, the SOMS International Congress on Obesity and Metabolic Syndrome is hosted by the Korean Society for the Study of Obesity and Metabolism. It attracted over 800 experts and scholars from China, Japan, South Korea, Chinese Taipei, and other countries and regions. Dr. Li's presentation highlighted the company's leading position in innovative drug development for metabolic diseases and demonstrated to global experts the new possibilities of "healthy weight loss."
This year's congress centered on the theme of "Precision Obesity Management and Lifelong Protection." A key clinical challenge that drew widespread discussion was "sarcopenic obesity" — the coexistence of obesity accompanied by muscle mass loss. Data show that approximately 30% of obese individuals experience muscle loss during weight loss, which can lead to decreased metabolism and an increased risk of weight regain.
Focus on HP515 Combined with GLP-1 Therapies
In his presentation, Dr. Li Xinghai noted that HP515 is an oral, highly selective THR-β (thyroid hormone receptor beta) agonist independently developed by the company and is currently being developed for the treatment of metabolic dysfunction-associated fatty liver disease / metabolic dysfunction-associated steatohepatitis (MAFLD/MASH) and obesity.
In preclinical studies, HP515 not only significantly reduced plasma and hepatic lipid levels but also demonstrated prominent synergistic advantages when combined with GLP-1 receptor agonists (such as semaglutide):
Potent Weight Loss: HP515 (10 mg/kg) combined with semaglutide (10 nmol/kg) achieved a 37.2% reduction in body weight, significantly outperforming semaglutide monotherapy (15.1%).
· Muscle Protection and Improved Body Composition: The combination therapy significantly increased the lean mass-to-body-weight ratio to 65.0% while reducing fat, even exceeding the normal-diet control group (63.6%), whereas the semaglutide monotherapy group achieved only 52.3%. This means that valuable skeletal muscle mass was effectively preserved during efficient weight loss.
· Mechanistic Insights: The study found that the combination therapy promoted thermogenesis by upregulating fatty acid metabolism-related genes (such as CYP2E1 and UCP1), thereby mechanistically explaining its synergistic effect. Similar results were observed with the combination of HP515 and tirzepatide.
HP515 Clinical Progress Promising
At the congress, Dr. Li further introduced that HP515, intended for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), has completed its Phase I clinical trial. In studies with single doses up to 200 mg and multiple doses up to 80 mg/day (for 14 consecutive days), HP515 demonstrated good safety and tolerability, as well as robust pharmacokinetic profiles.
HP515 exhibited good safety and tolerability with single doses escalated up to 200 mg and multiple doses escalated up to 80 mg/day (administered continuously for 14 days), with no cardiac toxicity signals observed, demonstrating 内部技能lent THR-β receptor agonist selectivity. Under conditions of 40 mg, 60 mg, and 80 mg once-daily dosing for 14 consecutive days, SHBG (sex hormone-binding globulin) showed a significant dose-dependent increase from baseline. At the 80 mg dose, SHBG increased by 176% after 14 days of dosing, indicating that HP515 exerts its pharmacological effects through activation of the endogenous THR-β receptor. Currently, HP515 is undergoing Phase II clinical trials.
Previously, preclinical research data on HP515 in combination with GLP-1R agonists for the treatment of obesity were presented as an oral report at the 32nd European Congress on Obesity (ECO) 2025 and were selected for poster presentation at The 3rd Obesity & Weight Loss Drug Development Summit in June 2025, signifying international recognition of the related research data by top-tier academic conferences.
- Hinova's Clinical Trial Application for the Combination of HP501 Sustained-release Tablets and xanthine oxidase inhibitors in the Treatment of Hyperuricemia/Gout was Accepted by NMPA
- Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
- Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
- Hinova Announces Phase III Clinical Trial of Deutenzalutamide (HC-1119) in Chinese Patients with castration-resistant prostate cancer (mCRPC) Met Primary Endpoint
- Hinova Today Listed on the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange (SSE) in China, Relying on PROTAC and Deuterium Technology to Develop Innovative D


